Your browser doesn't support javascript.
Uptake of COVID-19 Booster Dose among Saudi Arabian Population.
Alshahrani, Najim Z; Alsabaani, Abdullah A; Ridda, Iman; Rashid, Harunor; Alzahrani, Faris; Almutairi, Talal Hamed; Alzahrani, Bader Ahmed S; Albeshri, Abdulelah Saleh Saeed.
  • Alshahrani NZ; Department of Family and Community Medicine, Faculty of Medicine, University of Jeddah, Jeddah 21589, Saudi Arabia.
  • Alsabaani AA; Department of Family and Community Medicine, College of Medicine, King Khalid University, Abha 62529, Saudi Arabia.
  • Ridda I; Department of Public Health, National University of Natural Medicine, Portland, OR 97201, USA.
  • Rashid H; National Centre for Immunisation Research and Surveillance (NCIRS), Westmead, NSW 2145, Australia.
  • Alzahrani F; Discipline of Child and Adolescent Health, The Children's Hospital at Westmead Clinical School, Westmead, NSW 2145, Australia.
  • Almutairi TH; Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Biological Sciences and Sydney Medical School, The University of Sydney, Westmead, NSW 2145, Australia.
  • Alzahrani BAS; Department of Public Health, General Directorate of Health Affairs in Aseer Region, Ministry of Health, Abha 62523, Saudi Arabia.
  • Albeshri ASS; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh 14611, Saudi Arabia.
Medicina (Kaunas) ; 58(7)2022 Jul 21.
Article in English | MEDLINE | ID: covidwho-1957389
ABSTRACT
Backgroundand

objectives:

Although several vaccines have been produced and administered around the world, new SARS-CoV-2 worsened the COVID-19 infection risk and impacted the initial vaccine dosage effectiveness. Based on studies indicating that the third and fourth COVID-19 vaccine doses significantly reduced COVID-19 transmission, Saudi Arabia has been administering COVID-19 booster vaccine doses to its citizens. The purpose of this study was to evaluate the uptake of the COVID-19 vaccine booster in relation to the socio-demographic characteristics and other associated factors among the Saudi population. Materials and

Methods:

This study was an online analytical cross-sectional study using a self-administered questionnaire. Pearson Chi-square test and multiple logistic regression analyses were used to determine factors associated with the uptake of COVID-19 booster dose vaccines.

Results:

A total of 2332 responded to our study. Overall, 527 (22.6%) participants had received a booster dose. An age of 55 and above (aOR 5.415; 95% CI 2.719-10.783), Eastern region (aOR 2.513; 95% CI 1.566-4.033), history of influenza vaccination at annual intervals (aOR 2.387; 95% CI 1.730-3.293), the first dose of Moderna vaccine (aOR 1.324; 95% CI 1.160-1.510), and cancer (aOR 2.161; 95% CI 1.218-3.879) were independent factors most associated with a higher uptake of the COVID-19 vaccine booster dose. In contrast, the second dose of Moderna vaccine (aOR 0.794; 95% CI 0.683-0.922), AstraZeneca vaccine (aOR 0.691; 95% CI 0.509-0.939), strong symptoms from side effects after the second dose of the COVID-19 vaccine (aOR 0.615; 95% CI 0.404-0.935) were independent factors most associated with a lower uptake of the COVID-19 vaccine booster dose.

Conclusions:

Our findings indicate low COVID-19 vaccine booster uptake. This necessitates the need for strategies to address discouraging factors of the COVID-19 vaccine booster dose uptake and engage the Saudi population to raise awareness about the importance of the booster dose.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Medicina58070972

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Medicina58070972